Neovasc NVCN 深 沪

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow announced the presentation of three studies supporting IHEEZO® and BYOOVIZ® at the ASRS 2026 Annual Meeting. The studies expand clinical and real-world evidence for Harrow's retina portfolio. IHEEZO showed promising trends in reducing post-procedure pain and improving patient experience, while BYOOVIZ demonstrated safety and effectiveness in real-world use. Harrow emphasized its commitment to generating quality evidence to support long-ter...

07-20 11:00

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Expanded cohorts showed sustained improvements in vision, retinal anatomy, and pharmacokinetics, supporting extended treatment durability. TH103 demonstrated greater intraocular retention compared to leading anti-VEGF agents, with 41% of treatment-naive patients requiring retre...

07-17 11:00

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Ocular Therapeutix, Inc. will participate in several scientific and investor conferences in July 2026, including the OIS Retina Innovation Summit and the ASRS Annual Meeting in Montréal. Key presentations will focus on retinal disease treatments, including data from the Phase 3 SOL-1 trial for axitinib hydrogel (OTX-TKI) in neovascular AMD. The company will also host a fireside chat at the HC Wainwright Ophthalmology Virtual Conference. Ocular is...

07-01 11:00

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

4D Molecular Therapeutics will present a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, on July 18, 2026. The presentation, titled "2-Year Follow-Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population," will discuss the long-term results of their gene therapy for neovascular age-rel...

06-30 20:05

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Therapeutics will present Phase 1a clinical data for TH103, a novel dual-targeting biologic, at CTS 2026 on June 13, 2026. The presentation, led by Karl Csaky, MD, PhD, will showcase results from treatment-naïve patients with neovascular AMD. TH103, developed by Dr. Napoleone Ferrara, targets VEGF and HSPG to enhance intraocular retention and VEGF inhibition, with potential applications for wet AMD, diabetic eye disease, and retinal vein ...

06-12 12:00

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix, Inc. will participate in Clinical Trials at the Summit 2026 in Las Vegas, presenting updates on its OTX-TKI product candidate for retinal diseases, including wet AMD and diabetic retinopathy. The company will also discuss its pipeline leveraging ELUTYX technology, with DEXTENZA approved for ocular inflammation and OTX-TIC in Phase 2 for glaucoma. Exact presentation times may change.

06-04 11:00

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal

06-01 20:48

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

04-27 11:00

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Biogen to acquire Apellis for $41 per share, totaling approximately $5.6 billion, to gain two commercialized immunology medicines: EMPAVELI for rare kidney diseases and SYFOVRE for geographic atrophy. The deal, expected to close in 2Q2026, aims to boost Biogen's growth, with combined 2025 revenues of $689 million, projected to grow at mid-to-high teens through 2028. Apellis' capabilities will enhance Biogen's nephrology presence and support felza...

03-31 10:59

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Apellis Pharmaceuticals will present eight abstracts at the 49th Macula Society Annual Meeting, highlighting five-year results from the GALE study demonstrating SYFOVRE's impact in delaying geographic atrophy (GA) progression. SYFOVRE, the first approved treatment for GA secondary to age-related macular degeneration, showed improved outcomes with early and continuous use. Other presentations include real-world treatment patterns, AI applications,...

02-19 12:00